Abstract:Cardiac hypertrophy is characterized by an increase in cell size in the absence of cell division and is accompanied by a number of qualitative and quantitative changes in gene expression. Most forms of hypertrophy in vivo are compensatory or adaptative responses to increased workload resulting from various physiological and/or pathological etiologies. Until severe pathological alterations become apparent, myocytes show no drastic morphological changes. On the level of gene expression, upregulation of the so-called fetal genes, i.e., beta-myosin heavy chain, alpha-skeletal and alpha-smooth muscle actin, and atrial natriuretic factor (ANF) may be observed concomitant with a downregulation of alpha-myosin heavy chain and the Ca pump of sarcoplasmic reticulum. The use of primary cell culture systems for cardiomyocytes as an in vitro model for the hypertrophic reaction has identified a number of different stimuli as mediators of cardiac myocyte hypertrophy. The molecular dissection of the different intracellular signaling pathways involved herein has uncovered a number of branching points to cytosolic and nuclear targets and has identified many interactions between these pathways. The individual administration of these hypertrophic stimuli, i.e., hormones, cytokines, growth factors, vasoactive peptides, and catecholamines, to cultured cardiomyocytes, reveals that each stimulus induces a distinct phenotype as characterized by gene expression pattern and cellular morphology. Surprisingly, triiodothyronine (T3) and basic fibroblast growth factor (bFGF) effect a similar cellular phenotype although they use completely different intracellular pathways. This phenotype is characterized by drastic inhibition of myofibrillar growth and by upregulation of alpha-smooth muscle actin. On the other hand, insulin-like growth factor (IGF) I, a factor promoting muscle cell differentiation, and bFGF, an inhibitor of differentiation, cause completely different cardiomyocyte phenotypes although both are known to signal via receptor tyrosine kinases and have been shown to activate the Ras-Raf-MEK-MAP kinase pathway. However, both IGF-I and bFGF depend on T3 to bring about their typical responses, i.e., T3 is permissive for the action of these two growth factors on the expression of alpha-smooth muscle actin and cell morphology. Most of the hypertrophic stimuli are balanced under normal circumstances in vivo. When this balance is disturbed, however, a pathological heart phenotype may become dominant. Thus the knowledge of signaling pathways and cellular responses triggered by hypertrophic stimuli may be essential for the implementation of therapeutic strategies in the treatment of cardiac hypertrophy.

Single-molecule Imaging Revealed Enhanced Dimerization of Transforming Growth Factor Β Type II Receptors in Hypertrophic Cardiomyocytes

Transforming Growth Factor Beta (Tgf-Β) Mediates Cardiac Fibrosis and Induces Diabetic Cardiomyopathy

Monomeric Type I and Type III Transforming Growth Factor-Β Receptors and Their Dimerization Revealed by Single-Molecule Imaging

Dectin-1 Acts As a Non-Classical Receptor of Ang II to Induce Cardiac Remodeling.

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Single Molecule Fluorescence Imaging Reveals Monomeric Transforming Growth Factor-ΒETA Receptors

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Transcriptional Upregulation of Calcineurin Aβ by Endothelin-1 is Partially Mediated by Calcium/calmodulin-Dependent Protein Kinase IIδ3 in Rat Cardiomyocytes

Understanding The Role Of Transforming Growth Factor-Beta Signalling In The Heart: Overview Of Studies Using Genetic Mouse Models

The crystallin alpha B (HSPB5)-tripartite motif containing 33 (TRIM33) axis mediates myocardial fibrosis induced by angiotensinogen II through transforming growth factor-β (TGF-β1)-Smad3/4 signaling

Abstract 298: Flavin Containing Monooxygenase 2 in Cardiac Fibrosis

Quantitative Characterization of the Membrane Dynamics of Newly Delivered TGF-β Receptors by Single-Molecule Imaging

Single-molecule Force Spectroscopy Study of Interaction Between Transforming Growth Factor Beta1 and Its Receptor in Living Cells.

MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways

Cellular signal transduction in cardiac hypertrophy

TSC-22 Promotes Transforming Growth Factor Β-Mediated Cardiac Myofibroblast Differentiation by Antagonizing Smad7 Activity

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

MicroRNA-19a-3p augments TGF-β1-induced cardiac fibroblast activation via targeting BAMBI

Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes

Alteration in tyrosine phosphorylation of cardiac proteome and EGFR pathway contribute to hypertrophic cardiomyopathy